ENTITY
Remegen

Remegen (9995 HK)

186
Analysis
Health CareChina
RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.
more
Refresh
bullishRemegen
23 Oct 2020 10:37

Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48

This article analyzed two core products from RemeGen: RC18 and RC 48. The commercialization of these two products would have direct impact on the...

Logo
399 Views
Share
bullishRemegen
13 Aug 2020 10:04

RemeGen (荣昌生物) Pre-IPO: Thoughts on Valuation of RC18 and RC48

RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...

Logo
686 Views
Share
bullishRemegen
30 Jul 2020 16:29

RemeGen (荣昌生物) Pre-IPO: Top-Notch R&D Capability and a Strong Team

RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...

Logo
517 Views
Share
17 Sep 2023 10:10

A-H Premium Weekly (Sep 15th): Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec Oilfield

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Postal Savings, Sinopec Corp, Shanghai Fudan, Sinopec...

Logo
441 Views
Share
x